Researchers at Emory University are recruiting patients for a phase III clinical trial (XSEL) for systemic lupus erythematosus. If you qualify for and participate in this study, you may receive the investigational medication or placebo (inactive) treatment.
Volunteers will immediately receive steroid injections and stop some of the medication that’s not currently working for them. When and if the improvement from the steroid injections wears off, patients and their doctors can choose any standard of care treatment and receive it immediately.
Who qualifies for this study?
You may qualify for this study if you:
• Are 18 to 65 years old
• Have been diagnosed with systemic lupus erythematosus (SLE) — if you’re not sure if this is you, contact the study coordinator to find out if you qualify.
• Have active symptoms not fully controlled by your medications
The study doctor will evaluate additional information about you to see if you meet all of the criteria for participation in the study.
For more information, please contact Hinel Patel:
Clinical Research Coordinator
Emory University Hospital
Clinically Integrated Network Unit
1364 Clifton Road
Atlanta, Georgia, 3o322
More about Lupus
Lupus affects everyone differently, and the erratic nature of your symptoms can be frustrating. The disease most often affects the skin and joints, but it can potentially lead to inflammation in almost any organ in the body.
Because lupus flares and fades, often coupled with chronic pain and fatigue, individual symptoms are often similar to those of other diseases, and lupus takes an average of six years to fully diagnose. While lupus has no cure, some medications may help lessen the uncomfortable symptoms of lupus and can make flare-ups more manageable.
Nevertheless, the erratic coming and going of symptoms makes it difficult to plan for life and work. We need improved treatments for lupus.